A 24-week, prospective, pilot, randomized, open, parallel-group, active-comparator controlled trial to study dapagliflozin may attenuate adipose tissue inflammation and arterial stiffness in type 2 diabetes.

Trial Profile

A 24-week, prospective, pilot, randomized, open, parallel-group, active-comparator controlled trial to study dapagliflozin may attenuate adipose tissue inflammation and arterial stiffness in type 2 diabetes.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2015

At a glance

  • Drugs Dapagliflozin (Primary) ; Saxagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2015 New trial record
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top